EXEL Exelixis, Inc. - Common Stock
$52,86
Cena · Sie 18, 2026
Dane fundamentalne na dzień Sie 5, 2026
Zakres 52 tyg.
$34–$58
80% of range
Ocena Analityków
HOLD
26 analysts
Cena Docelowa
$53
+0% upside
P/E (TTM)
18.4
ROE
37.3%
Marża Zysku Netto
33.7%
O Exelixis, Inc. - Common Stock Przegląd firmy z Wikipedii
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Czytaj więcej
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
History
Exelixis was founded in 1994; the scientific founders were Spyridon Artavanis–Tsakonas, at Yale at that time, and Corey Goodman and Gerry Rubin who were then at the University of California, Berkeley. George Scangos joined the company as CEO in 1996. The business plan was to use model organisms (fruit flies, nematodes, and zebrafish) and functional genomics to identify pathways and biological targets that could be exploited in the fields of agriculture and medicine. It eventually set up a subsidiary, Exelixis Plant Sciences, for the agricultural work.
By 2000, Exelixis had left the radical exploratory phase behind and became focused on drug discovery and had a chemical library of 4 million compounds. The company went public that year, after withdrawing its offering the week before; it raised $118 million in a down market.
In 2002, the company signed a broad alliance with GSK to discover new drugs in the fields of cancer, inflammatory diseases, and vascular conditions; GSK paid it $30 million in cash, bought $14 million in stock at twice the market rate, and committed to providing Exelixis with $90 million in research funding; it also offered loan financing of up to $85 million.
By 2002, the company had limited its internal efforts to cancer, and had settled its strategy on discovering and developing drugs that could inhibit targeted small sets of tyrosine kinases that are needed for cancer formation, growth, and metastasis. The sets of TKs had been identified by means of its prior functional genomics work. This approach was controversial at the time; most companies try to selectively target just one protein in their discovery efforts.
In 2006, Exelixis partnered with Daiichi Sankyo on compounds that targeted mineralocorticoid receptors; esaxerenone was part of this collaboration. In 2007, the company partnered its MEK inhibitor program with Genentech; cobimetinib (at that time XL-518) was part of this collaboration. Exelixis had filed an IND on XL-518 prior to the partnership, committed to funding and running the Phase I trial, and retained rights to co-market it in the US.
In 2008, the company partnered its lead cancer drug candidate, XL-184 (which would become called cabozantinib) and another cancer candidate, XL-281, with Bristol Myers Squibb; BMS returned the rights to XL-184 to Exelixis in 2010 and returned the rights to other drug candidate in 2011.
In 2010, Scangos departed as CEO to take over at Biogen and the company appointed Michael M. Morrissey as president and CEO; Morrissey had joined the company in 2000 as Vice President of Discovery Research. At that time the company had eight drugs in clinical trials.
Exelixis' first drug approval came in 2012, when cabozantinib was approved for medullary thyroid cancer, an orphan indication. It was approved in Europe in 2014.
Exelixis invested heavily in exploring cabozantinib in other cancers, betting the future of the company on the drug. In 2014 the drug failed a Phase III trial in prostate cancer, and the company laid off 70% of its employees.
In 2015, Genentech and Exelixis won FDA approval for cobimetinib for certain forms of melanoma.
In March 2016, Exelixis licensed to Ipsen worldwide rights (outside the US, Canada, and Japan) to market cabozantinib.
In April 2016, the FDA granted approval for marketing the tablet formulation as a second line treatment for kidney cancer and the same was approved in Europe in October of that year.
In December 2017, the FDA granted approval for the use of cabozantinib for first line treatment of kidney cancer and in 2018 approval for first-line treatment was approved in Europe.
Finance
Pricing
Cabometyx (cabozantinib)
In 2023, the Institute for Clinical and Economic Review (ICER) identified Cabometyx (cabozantinib) as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence to justify the hikes. Specifically, Cabometyx's wholesale acquisition cost rose by 7.5%, leading to an additional $86 million in costs to U.S. payers.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
EXEL Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$52.86
Kapitalizacja Rynkowa
$13.41B
P/E (TTM)
18.4
EPS (TTM)
$2.78
Przychody (TTM)
$2.32B
Stopa dywidendy
—
ROE
37.3%
D/E Dług/Kapitał
—
Zakres 52 tyg.
$34 – $58
EXEL Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$2.32B
2016-12-31
→
2026-01-02
EPS
$2.78
2017-12-29
→
2026-01-02
Wolny przepływ pieniężny
$876M
2017-12-29
→
2026-01-02
Marże
33.7%
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
EXEL
Mediana porównawcza
P/E (TTM)
18.4
28.5
P/S (TTM)
5.8
20.1
P/B
6.2
12.9
Price / FCF (Cena / FCF)
15.3
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
EXEL
Mediana porównawcza
Operating Margin (Marża Operacyjna)
37.6%
—
Net Profit Margin (Marża Zysku Netto)
33.7%
-48.4%
ROA
27.0%
-28.4%
ROE
37.3%
-49.2%
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
EXEL
Mediana porównawcza
Current Ratio (Wskaźnik bieżący)
3.6
5.0
Quick Ratio (Wskaźnik Szybkości)
3.3
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
EXEL
Mediana porównawcza
Revenue YoY (Przychody R/R)
7.0%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
12.9%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
18.6%
—
EPS YoY
58.0%
—
Net Income YoY (Zysk Netto R/R)
50.1%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
EXEL
Mediana porównawcza
EXEL Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
26 analityków
- Mocne kupno 5 19,2%
- Kup 8 30,8%
- Trzymaj 12 46,2%
- Sprzedaj 1 3,8%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
16 analityków · 2026-08-13
Mediana
$52.00
Teraz
$52.86
Niski
$41.00
Wysoki
$66.00
Średni cel
$52.00
-1,6%
Średnia cel
$52.94
+0,1%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
0.08%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $0.82 | $0.80 | 0.02% |
| 31 marca 2026 | $0.79 | $0.72 | 0.07% |
| 31 grudnia 2025 | $0.88 | $0.82 | 0.06% |
| 30 września 2025 | $0.69 | $0.63 | 0.06% |
| 30 czerwca 2025 | $0.65 | $0.57 | 0.08% |
| 31 marca 2025 | $0.55 | $0.37 | 0.18% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 16
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $988M | $968M | $854M | $452M | $191M | $37M | |
| Cost of Revenue | $84M | $76M | $73M | $58M | $53M | $36M | $33M | $26M | $15M | $7M | $4M | |
| R&D Expense | $825M | $910M | $1.04B | $892M | $694M | $548M | $337M | $182M | $112M | $96M | $96M | |
| SG&A Expense | $519M | $492M | $543M | $460M | $402M | $293M | $228M | $206M | $159M | $116M | $57M | |
| Operating Expenses | $1.45B | $1.56B | $1.66B | $1.41B | $1.15B | $877M | $598M | $415M | $287M | $220M | $159M | |
| Operating Income | $872M | $605M | $171M | $201M | $287M | $110M | $369M | $439M | $166M | $-28M | $-121M | |
| Interest Expense | · | · | · | · | · | · | $0 | $0 | $9M | $33M | $41M | |
| Other Non-op | $-198.0K | $-133.0K | $93.0K | $-197.0K | $-184.0K | $912.0K | $680.0K | $397.0K | $-4M | $5M | $-381.0K | |
| Pretax Income | · | · | · | · | · | $131M | $398M | $452M | $159M | $-70M | $-162M | |
| Income Tax | $159M | $160M | $50M | $52M | $63M | $19M | $77M | $-238M | $4M | $0 | $55.0K | |
| Net Income | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | $-70M | $-162M | |
| EPS (Basic) | $2.88 | $1.80 | $0.65 | $0.57 | $0.73 | $0.36 | $1.06 | $2.32 | $0.52 | · | $-0.77 | |
| EPS (Diluted) | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 | $0.35 | $1.02 | $2.21 | $0.49 | · | $-0.77 | |
| Shares (Basic) | 271,567,000 | 290,030,000 | 318,151,000 | 321,526,000 | 314,884,000 | 308,271,000 | 302,584,000 | 297,892,000 | 293,588,000 | · | 209,227,000 | |
| Shares (Diluted) | 281,863,000 | 296,132,000 | 321,464,000 | 324,556,000 | 322,359,000 | 318,001,000 | 315,009,000 | 312,803,000 | 312,003,000 | · | 209,227,000 | |
| EBITDA | $901M | $633M | $197M | $222M | $300M | $119M | $378M | $444M | $167M | · | · |
Bilans 27
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $482M | $217M | $263M | $501M | $647M | $319M | $267M | $315M | $183M | $152M | $142M | |
| Short-term Investments | $577M | $894M | $732M | $807M | $820M | $887M | $586M | $379M | $205M | $268M | · | |
| Receivables | $287M | $265M | $237M | $215M | $283M | $161M | $119M | $163M | $77M | $40M | · | |
| Inventory | $22M | $22M | $17M | $33M | $27M | $21M | $13M | $10M | $7M | $3M | · | |
| Prepaid Expense | $76M | $68M | $68M | $62M | $58M | $57M | $27M | $31M | $9M | $5M | · | |
| Current Assets | $1.44B | $1.47B | $1.32B | $1.62B | $1.83B | $1.45B | $1.01B | $897M | $485M | $469M | · | |
| PP&E (Net) | $99M | $119M | $129M | $111M | $104M | $67M | $49M | $51M | $26M | $2M | · | |
| PP&E (Gross) | $231M | $220M | $209M | $171M | $145M | $102M | $74M | $68M | $49M | $27M | · | |
| Accum. Depreciation | $132M | $101M | $80M | $61M | $41M | $35M | $26M | $17M | $23M | $25M | · | |
| Goodwill | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | · | |
| Other Non-current Assets | · | · | · | · | $131M | $73M | $53M | $8M | $12M | $1M | · | |
| Total Assets | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B | $2.14B | $1.89B | $1.42B | $655M | $596M | · | |
| Accounts Payable | $30M | $38M | $34M | $33M | $24M | $24M | $12M | $11M | $10M | $7M | · | |
| Short-term Debt | · | · | · | · | · | · | · | · | $0 | $80M | · | |
| Current Liabilities | $406M | $404M | $394M | $324M | $338M | $205M | $143M | $105M | $115M | $269M | · | |
| Capital Leases | $173M | $191M | $190M | $190M | $51M | $49M | $48M | $12M | $15M | · | · | |
| Other Non-current Liabilities | $104M | $109M | $94M | $69M | $8M | $721.0K | $2M | $1M | $2M | $541.0K | · | |
| Total Liabilities | $683M | $703M | $678M | $583M | $406M | $258M | $200M | $135M | $370M | $506M | · | |
| Long-term Debt | · | · | · | · | · | · | · | · | $0 | $189M | · | |
| Total Debt | · | · | · | · | · | · | · | · | $0 | · | · | |
| Common Stock | $262.0K | $282.0K | $303.0K | $324.0K | $319.0K | $312.0K | $305.0K | $300.0K | $296.0K | $290.0K | · | |
| Paid-in Capital | $2.23B | $2.34B | $2.44B | $2.54B | $2.43B | $2.32B | $2.24B | $2.17B | $2.11B | $2.07B | · | |
| Retained Earnings | $-77M | $-99M | $-173M | $-34M | $-217M | $-448M | $-559M | $-880M | $-1.83B | $-1.98B | · | |
| AOCI | $3M | $-1M | $-4M | $-15M | $-758.0K | $4M | $3M | $-701.0K | $-347.0K | $-416.0K | · | |
| Stockholders' Equity | $2.16B | $2.24B | $2.26B | $2.49B | $2.21B | $1.88B | $1.69B | $1.29B | $285M | $89M | $-141M | |
| Liabilities + Equity | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B | $2.14B | $1.89B | $1.42B | $655M | $596M | · | |
| Shares Outstanding | 262,483,000 | 281,732,000 | 302,793,000 | 323,951,000 | 318,842,000 | 311,627,000 | 304,831,000 | 299,876,000 | 296,209,000 | 289,923,798 | 227,960,943 |
Przepływy pieniężne 17
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $29M | $29M | $26M | $21M | $14M | $9M | $8M | $5M | $1M | $1M | $1M | |
| Stock-based Comp | $113M | $94M | $106M | $108M | $120M | $105M | $57M | $41M | $24M | $23M | $22M | |
| Deferred Tax | $126M | $-59M | $-133M | $-60M | $47M | $15M | $71M | $-244M | $0 | $0 | $0 | |
| Restructuring | $21M | $34M | $0 | $0 | · | · | · | $0 | $-32.0K | $63M | $1M | |
| Other Non-cash | $-167M | $116M | $127M | $112M | $-10M | $-32M | $70M | $-76M | $-14M | · | · | |
| Operating Cash Flow | $884M | $700M | $333M | $363M | $401M | $209M | $527M | $416M | $166M | $206M | $-141M | |
| CapEx | $8M | $28M | $40M | $28M | $54M | $30M | $13M | $33M | $21M | $2M | $447.0K | |
| Investing Cash Flow | $350M | $-117M | $-27M | $-524M | $-43M | $-131M | $-587M | $-298M | $37M | $-216M | $50M | |
| Net Debt Issued | · | · | · | · | · | · | $0 | $0 | $-186M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $0 | $0 | $146M | |
| Stock Repurchased | $948M | $652M | $550M | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | $-948M | $-652M | $-550M | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $-970M | $-629M | $-546M | $586.0K | $-15M | $-25M | $13M | $10M | $-170M | $20M | $152M | |
| Net Change in Cash | $265M | $-46M | $-240M | $-161M | $343M | $53M | $-48M | $128M | $32M | $10M | $61M | |
| Taxes Paid | $155M | $170M | $186M | $128M | $13M | $4M | $8M | $11M | $538.0K | · | · | |
| Free Cash Flow | $876M | $672M | $293M | $335M | $337M | $179M | $514M | $382M | $144M | · | · | |
| Levered FCF | · | · | · | · | · | · | $514M | $382M | $136M | · | · |
Rentowność 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | 11.1% | 38.2% | 51.4% | 36.7% | · | · | |
| Net Margin | 33.7% | 24.0% | 11.3% | 11.3% | 16.1% | 11.3% | 33.2% | 80.8% | 34.1% | · | · | |
| Pretax Margin | · | · | · | · | · | 13.2% | 41.1% | 52.9% | 35.0% | · | · | |
| EBITDA Margin | 38.8% | 29.2% | 10.7% | 13.8% | 20.9% | 12.1% | 39.0% | 52.0% | 36.9% | · | · | |
| ROA | 27.0% | 17.7% | 6.9% | 6.4% | 9.7% | 5.6% | 19.4% | 66.4% | 24.7% | · | · | |
| ROE | 37.3% | 23.1% | 9.0% | 7.3% | 10.7% | 6.0% | 19.5% | 62.6% | 82.4% | · | · | |
| ROIC | · | · | · | · | · | 5.0% | 17.7% | 52.0% | 56.6% | · | · |
Płynność i wypłacalność 4
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | 3.6 | 3.3 | 5.0 | 5.4 | 7.1 | 7.1 | 8.5 | 4.2 | · | · | |
| Quick Ratio | 3.3 | 3.4 | 3.1 | 4.7 | 5.2 | 6.7 | 6.8 | 8.1 | 4.1 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 0.0 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 19.1 | · | · |
Efektywność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.7 | 0.6 | 0.6 | 0.6 | 0.5 | 0.6 | 0.8 | 0.7 | · | · | |
| Inventory Turnover | 3.8 | 3.8 | 2.9 | 1.9 | 2.2 | 2.1 | 2.9 | 3.2 | 3.0 | · | · | |
| Receivables Turnover | 8.4 | 8.6 | 8.1 | 6.5 | 6.5 | 7.1 | 6.9 | 9.8 | 7.4 | · | · |
Stopy Wzrostu 9
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.0% | 18.5% | 13.6% | 12.3% | 45.3% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 12.9% | 14.8% | 22.8% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 18.6% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 58.0% | 170.8% | 16.1% | -22.2% | 105.7% | · | · | · | · | · | · | |
| EPS CAGR 3Y | 70.6% | 34.7% | 22.9% | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 51.3% | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 50.1% | 150.9% | 14.0% | -21.1% | 106.7% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 62.5% | 31.1% | 22.9% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 47.6% | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 14
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $988M | $968M | $854M | $452M | · | $37M | |
| Net Income TTM | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | · | $-162M | |
| Market Cap | $11.44B | $9.57B | $7.26B | $5.20B | $5.83B | $6.25B | $5.19B | $5.83B | $9.00B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $8.62B | · | · | |
| P/E | 15.7 | 19.3 | 36.9 | 28.6 | 25.4 | 57.3 | 16.7 | 8.8 | 62.0 | · | -7.3 | |
| P/S | 4.9 | 4.4 | 4.0 | 3.2 | 4.1 | 6.3 | 5.4 | 6.8 | 19.9 | · | · | |
| P/B | 5.3 | 4.3 | 3.2 | 2.1 | 2.6 | 3.3 | 3.1 | 4.5 | 31.6 | · | · | |
| P / Tangible Book | 5.5 | 4.4 | 3.3 | 2.1 | 2.7 | 3.4 | · | · | · | · | · | |
| P / Cash Flow | 12.9 | 13.7 | 21.8 | 14.3 | 14.5 | 29.9 | 9.8 | 14.0 | 54.4 | · | · | |
| P / FCF | 13.1 | 14.3 | 24.8 | 15.5 | 17.3 | 35.0 | 10.1 | 15.2 | 62.3 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | 51.6 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | 59.6 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 19.0 | · | · | |
| Earnings Yield | 6.4% | 5.2% | 2.7% | 3.5% | 3.9% | 1.7% | 6.0% | 11.4% | 1.6% | · | -13.7% |
Rachunek zysków i strat 14
| Wskaźnik | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $629M | $611M | $718M | $598M | $568M | $555M | $818M | $540M | $637M | $425M | $480M | $472M | $470M | $409M | $424M | $412M | |
| Cost of Revenue | $21M | $20M | $27M | $19M | $19M | $19M | $25M | $17M | $18M | $21M | $22M | $19M | $18M | $14M | $16M | $15M | |
| R&D Expense | $212M | $200M | $164M | $199M | $200M | $212M | $111M | $223M | $211M | $228M | $245M | $333M | $233M | $234M | $337M | $199M | |
| SG&A Expense | $148M | $140M | $161M | $124M | $135M | $137M | $81M | $112M | $132M | $114M | $131M | $138M | $142M | $131M | $119M | $115M | |
| Operating Expenses | $380M | $359M | $287M | $361M | $355M | $369M | $303M | $403M | $361M | $396M | $398M | $490M | $392M | $380M | $472M | $329M | |
| Operating Income | $248M | $251M | $431M | $237M | $214M | $187M | $516M | $136M | $276M | $29M | $82M | $-18M | $78M | $29M | $-48M | $83M | |
| Other Non-op | $54.0K | $219.0K | $207.0K | $-49.0K | $50.0K | $-245.0K | $-363.0K | $-29.0K | $-287.0K | $-89.0K | $-137.0K | $289.0K | $-5.0K | $-54.0K | $-337.0K | $-69.0K | |
| Income Tax | $51M | $57M | $43M | $59M | $46M | $46M | $128M | $37M | $67M | $12M | $18M | $5M | $19M | $8M | $-1M | $19M | |
| Net Income | $212M | $210M | $401M | $194M | $185M | $160M | $399M | $118M | $226M | $37M | $86M | $1M | $81M | $40M | $-30M | $73M | |
| EPS (Basic) | $0.85 | $0.81 | $1.57 | $0.72 | $0.68 | $0.57 | $1.43 | $0.41 | $0.78 | $0.12 | $0.28 | $0.00 | $0.25 | $0.12 | $-0.09 | $0.23 | |
| EPS (Diluted) | $0.82 | $0.79 | $1.49 | $0.69 | $0.65 | $0.55 | $1.39 | $0.40 | $0.77 | $0.12 | $0.28 | $0.00 | $0.25 | $0.12 | $-0.09 | $0.23 | |
| Shares (Basic) | 250,808,000 | 258,329,000 | -604,028,000 | 268,421,000 | 272,583,000 | 278,804,000 | -674,091,000 | 285,622,000 | 289,216,000 | 300,757,000 | -645,970,000 | 315,496,000 | 324,205,000 | 324,420,000 | 577,000 | 322,148,000 | |
| Shares (Diluted) | 259,675,000 | 267,322,000 | -609,119,000 | 278,535,000 | 284,393,000 | 288,177,000 | -676,699,000 | 291,478,000 | 293,974,000 | 305,530,000 | -651,367,000 | 319,247,000 | 327,305,000 | 326,279,000 | 136,000 | 325,066,000 | |
| EBITDA | $248M | $258M | · | $237M | $214M | $194M | · | $136M | $276M | $36M | · | $-18M | $78M | $36M | · | $83M |
Bilans 24
| Wskaźnik | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $281M | $226M | $482M | $376M | $164M | $184M | $217M | $258M | $198M | $260M | · | $397M | $464M | $541M | · | $675M | |
| Short-term Investments | $558M | $551M | $577M | $612M | $627M | $848M | $894M | $931M | $804M | $704M | · | $707M | $802M | $773M | · | $872M | |
| Receivables | $322M | $329M | $287M | $310M | $292M | $282M | $265M | $270M | $397M | $241M | · | $248M | $233M | $234M | · | $215M | |
| Inventory | $29M | $27M | $22M | $27M | $23M | $25M | $22M | $21M | $21M | $21M | · | $25M | $29M | $30M | · | $27M | |
| Prepaid Expense | $60M | $76M | $76M | $77M | $74M | $59M | $68M | $70M | $58M | $67M | · | $67M | $62M | $61M | · | $53M | |
| Current Assets | $1.25B | $1.21B | $1.44B | $1.40B | $1.18B | $1.40B | $1.47B | $1.55B | $1.48B | $1.29B | · | $1.44B | $1.59B | $1.64B | · | $1.84B | |
| PP&E (Net) | $93M | $96M | $99M | $105M | $110M | $115M | $119M | $124M | $130M | $127M | · | $121M | $115M | $116M | · | $108M | |
| PP&E (Gross) | · | · | $231M | · | · | · | $220M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $132M | · | · | · | $101M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | $64M | · | $64M | $64M | $64M | · | $64M | |
| Other Non-current Assets | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $280M | |
| Total Assets | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B | $2.96B | $2.77B | $2.80B | · | $2.98B | $3.14B | $3.14B | · | $2.96B | |
| Accounts Payable | $39M | $24M | $30M | $25M | $26M | $43M | $38M | $59M | $29M | $26M | · | $26M | $26M | $33M | · | $31M | |
| Current Liabilities | $362M | $371M | $406M | $374M | $336M | $399M | $404M | $394M | $346M | $373M | · | $377M | $340M | $328M | · | $302M | |
| Capital Leases | $166M | $170M | $173M | $176M | $180M | $187M | $191M | $194M | $198M | $201M | · | $191M | $195M | $187M | · | $160M | |
| Other Non-current Liabilities | $123M | $117M | $104M | $113M | $129M | $120M | $109M | $96M | $110M | $101M | · | $62M | $73M | $67M | · | $2M | |
| Total Liabilities | $650M | $658M | $683M | $663M | $645M | $706M | $703M | $685M | $653M | $676M | · | $629M | $615M | $588M | · | $470M | |
| Common Stock | $249.0K | $254.0K | $262.0K | $268.0K | $270.0K | $275.0K | $282.0K | $286.0K | $285.0K | $295.0K | · | $311.0K | $320.0K | $325.0K | · | $323.0K | |
| Paid-in Capital | $2.11B | $2.15B | $2.23B | $2.26B | $2.25B | $2.29B | $2.34B | $2.36B | $2.32B | $2.39B | · | $2.49B | $2.53B | $2.56B | · | $2.51B | |
| Retained Earnings | $-263M | $-216M | $-77M | $-106M | $-220M | $-163M | $-99M | $-90M | $-200M | $-259M | · | $-126M | $11M | $6M | · | $-4M | |
| AOCI | $-2M | $-415.0K | $3M | $4M | $1M | $2M | $-1M | $4M | $-5M | $-5M | · | $-14M | $-14M | $-9M | · | $-18M | |
| Stockholders' Equity | $1.84B | $1.94B | $2.16B | $2.16B | $2.03B | $2.13B | $2.24B | $2.28B | $2.12B | $2.13B | $2.26B | $2.35B | $2.53B | $2.56B | $2.49B | $2.49B | |
| Liabilities + Equity | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B | $2.96B | $2.77B | $2.80B | · | $2.98B | $3.14B | $3.14B | · | $2.96B | |
| Shares Outstanding | 248,885,000 | 253,701,000 | 262,483,000 | 268,098,000 | 270,132,000 | 275,033,000 | 281,732,000 | 285,780,000 | 285,222,000 | 295,032,000 | 302,793,000 | 310,970,000 | 320,253,000 | 324,985,000 | 323,951,000 | 322,541,000 |
Przepływy pieniężne 12
| Wskaźnik | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $7M | $8M | $7M | $7M | $7M | $10M | $7M | $7M | $6M | $7M | $6M | $6M | $7M | $6M | $6M | |
| Stock-based Comp | $33M | $29M | $45M | $31M | $36M | $26M | $12M | $23M | $25M | $19M | $24M | $40M | $25M | $17M | $26M | $37M | |
| Restructuring | · | · | $-13M | $20M | $0 | $0 | $34M | $96.0K | $475.0K | $33M | · | $0 | $0 | $0 | · | · | |
| Other Non-cash | · | $5M | · | · | · | $19M | · | · | · | $6M | · | · | · | $21M | · | · | |
| Operating Cash Flow | $308M | $252M | $425M | $290M | $49M | $211M | $377M | $271M | $120M | $69M | $11M | $117M | $121M | $84M | $74M | $110M | |
| CapEx | $7M | $2M | $-16M | $1M | $3M | $3M | $1M | $8M | $7M | $10M | $13M | $9M | $6M | $12M | $10M | $43.0K | |
| Investing Cash Flow | $91M | $-51M | $374M | $25M | $248M | $50M | $-28M | $-217M | $82M | $112M | $62M | $35M | $-74M | $-50M | $-246M | $-69M | |
| Stock Repurchased | $323M | $430M | $486M | $104M | $302M | $284M | $311M | $12M | $264M | $185M | $209M | $217M | $124M | $0 | $0 | $0 | |
| Net Stock Activity | · | $-430M | · | · | · | $-284M | · | · | · | $-185M | · | · | · | · | · | · | |
| Financing Cash Flow | $-344M | $-457M | $-529M | $-104M | $-316M | $-295M | $-289M | $6M | $-262M | $-184M | $-206M | $-220M | $-125M | $5M | $-2M | $-2M | |
| Net Change in Cash | $55M | $-256M | $270M | $212M | $-19M | $-34M | $60M | $60M | $-61M | $-3M | $-134M | $-68M | $-78M | $39M | $-174M | $39M | |
| Free Cash Flow | · | $250M | · | · | · | $208M | · | · | · | $59M | · | · | · | $72M | · | · |
Rentowność 5
| Wskaźnik | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.5% | 41.1% | · | 39.6% | 37.6% | 33.6% | · | 25.2% | 43.3% | 6.9% | · | -3.7% | 16.6% | 7.0% | · | 20.1% | |
| Net Margin | 33.7% | 34.5% | · | 32.4% | 32.5% | 28.7% | · | 21.9% | 35.5% | 8.8% | · | 0.22% | 17.3% | 9.8% | · | 17.8% | |
| EBITDA Margin | 39.5% | 42.3% | · | 39.6% | 37.6% | 35.0% | · | 25.2% | 43.3% | 8.4% | · | -3.7% | 16.6% | 8.7% | · | 20.1% | |
| ROA | 8.2% | 7.8% | · | 6.7% | 6.8% | 5.7% | · | 4.0% | 7.6% | 1.2% | · | 0.04% | 2.7% | 1.4% | · | 2.7% | |
| ROE | 10.9% | 10.3% | · | 8.7% | 8.9% | 7.5% | · | 5.1% | 9.7% | 1.6% | · | 0.04% | 3.3% | 1.7% | · | 3.2% |
Płynność i wypłacalność 2
| Wskaźnik | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.3 | · | 3.8 | 3.5 | 3.5 | · | 3.9 | 4.3 | 3.5 | · | 3.8 | 4.7 | 5.0 | · | 6.1 | |
| Quick Ratio | 3.2 | 3.0 | · | 3.5 | 3.2 | 3.3 | · | 3.7 | 4.0 | 3.2 | · | 3.6 | 4.4 | 4.7 | · | 5.8 |
Efektywność 3
| Wskaźnik | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.8 | · | 0.8 | 0.7 | 0.8 | · | 0.7 | 0.6 | 0.5 | · | 0.6 | |
| Receivables Turnover | 2.0 | 2.0 | · | 2.1 | 1.6 | 2.1 | · | 2.1 | 2.0 | 1.8 | · | 2.0 | 2.0 | 1.9 | · | 2.1 |
Wycena (TTM) 10
| Wskaźnik | Trend | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2024 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.41B | $2.33B | · | $2.26B | $2.30B | $2.16B | · | $2.07B | $2.00B | $1.78B | · | $1.76B | $1.71B | $1.60B | · | $1.52B | |
| Net Income TTM | $801M | $749M | · | $656M | $689M | $541M | · | $382M | $346M | $160M | · | $195M | $265M | $252M | · | $251M | |
| Market Cap | $13.90B | $11.13B | · | $10.75B | $12.47B | $9.51B | · | $7.42B | $6.41B | $7.00B | · | $6.79B | $6.12B | $6.31B | · | $5.06B | |
| P/E | 18.9 | 16.4 | · | 17.5 | 19.5 | 18.8 | · | 20.1 | 19.7 | 48.4 | · | 36.4 | 23.3 | 24.9 | · | 20.1 | |
| P/S | 5.8 | 4.8 | · | 4.8 | 5.4 | 4.4 | · | 3.6 | 3.2 | 3.9 | · | 3.9 | 3.6 | 4.0 | · | 3.3 | |
| P/B | 7.5 | 5.8 | · | 5.0 | 6.1 | 4.5 | · | 3.3 | 3.0 | 3.3 | · | 2.9 | 2.4 | 2.5 | · | 2.0 | |
| P / Tangible Book | 7.8 | 5.9 | · | 5.1 | 6.3 | 4.6 | · | 3.4 | 3.1 | 3.4 | · | 3.0 | 2.5 | 2.5 | · | 2.1 | |
| P / Cash Flow | · | 44.2 | · | · | · | 45.0 | · | · | · | 101.7 | · | · | · | 74.7 | · | · | |
| P / FCF | · | 44.5 | · | · | · | 45.6 | · | · | · | 118.4 | · | · | · | 87.1 | · | · | |
| Earnings Yield | 5.3% | 6.1% | · | 5.7% | 5.1% | 5.3% | · | 5.0% | 5.1% | 2.1% | · | 2.8% | 4.3% | 4.0% | · | 5.0% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B |
| Marża Operacyjna % | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% |
| Zysk netto | $783M | $521M | $208M | $182M | $231M |
| Rozwodniony EPS | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 |
Bilans
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 3.6 | 3.6 | 3.3 | 5.0 | 5.4 |
| Wskaźnik Szybkości | 3.3 | 3.4 | 3.1 | 4.7 | 5.2 |
Przepływy pieniężne
| 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $876M | $672M | $293M | $335M | $337M |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Sygnały transakcyjne Ostatnie sygnały kupna/sprzedaży z ceną wejścia i wskaźnikiem ryzyka/zysku
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 811 emitentów · $9.1B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 135 (+27 vs poprzedni kw.) | 61 (-13 vs poprzedni kw.) | 240 (-1 vs poprzedni kw.) | 274 (+16 vs poprzedni kw.) | +39.8M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $732 794 424 | 13 468 010 | 8,04% | Akcje |
| RENAISSANCE TECHNOLOGIES LLC | $730 617 099 | 13 427 993 | 8,01% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $655 266 268 | 12 043 122 | 7,19% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $595 843 747 | 10 950 997 | 6,53% | Akcje |
| STATE STREET CORP | $542 471 563 | 9 970 071 | 5,95% | Akcje |
| FULLER & THALER ASSET MANAGEMENT, INC. | $485 848 030 | 8 929 389 | 5,33% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $362 702 104 | 6 664 894 | 3,98% | Akcje |
| D. E. Shaw & Co., Inc. | $281 389 313 | 5 171 647 | 3,09% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $237 550 034 | 4 365 926 | 2,60% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $229 058 537 | 4 209 861 | 2,51% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $221 832 835 | 4 077 060 | 2,43% | Akcje |
| ASSETMARK, INC | $186 834 364 | 3 433 824 | 2,05% | Akcje |
| Stephens Investment Management Group LLC | $147 451 698 | 2 710 011 | 1,62% | Akcje |
| NORGES BANK | $146 301 199 | 2 688 866 | 1,60% | Akcje |
| FIRST TRUST ADVISORS LP | $138 383 701 | 2 543 353 | 1,52% | Akcje |
| Caisse de depot et placement du Quebec | $113 950 809 | 2 094 299 | 1,25% | Akcje |
| GOLDMAN SACHS GROUP INC | $106 578 308 | 1 958 800 | 1,17% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $97 484 439 | 1 791 664 | 1,07% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $86 563 209 | 1 590 943 | 0,95% | Akcje |
| Caligan Partners LP | $84 512 985 | 1 553 262 | 0,93% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $66 309 793 | 1 218 706 | 0,73% | Akcje |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $63 086 055 | 1 159 457 | 0,69% | Akcje |
| BANK OF AMERICA CORP /DE/ | $58 788 318 | 1 080 469 | 0,64% | Akcje |
| Robeco Institutional Asset Management B.V. | $56 032 453 | 1 029 819 | 0,61% | Akcje |
| ENVESTNET ASSET MANAGEMENT INC | $51 671 488 | 949 669 | 0,57% | Akcje |
| FMR LLC | $48 839 667 | 897 623 | 0,54% | Akcje |
| Gotham Asset Management, LLC | $48 569 794 | 892 663 | 0,53% | Akcje |
| Swedbank AB | $45 801 141 | 841 778 | 0,50% | Akcje |
| Allspring Global Investments Holdings, LLC | $44 544 520 | 825 510 | 0,49% | Akcje |
| Retirement Systems of Alabama | $44 107 739 | 810 655 | 0,48% | Akcje |
| BOOTHBAY FUND MANAGEMENT, LLC | $43 750 809 | 804 095 | 0,48% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $41 924 320 | 770 526 | 0,46% | Akcje |
| Capital Impact Advisors, LLC | $41 061 268 | 754 664 | 0,45% | Akcje |
| BlackRock, Inc. | $40 753 525 | 749 008 | 0,45% | Akcje |
| RHUMBLINE ADVISERS | $35 723 294 | 656 559 | 0,39% | Akcje |
| CANADA PENSION PLAN INVESTMENT BOARD | $35 464 438 | 651 800 | 0,39% | Akcje |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $34 721 830 | 639 680 | 0,38% | Akcje |
| MARSHALL WACE, LLP | $34 322 590 | 630 814 | 0,38% | Akcje |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $34 315 027 | 630 675 | 0,38% | Akcje |
| AMERIPRISE FINANCIAL INC | $32 255 716 | 592 827 | 0,35% | Akcje |
| BARCLAYS PLC | $31 502 574 | 578 985 | 0,35% | Akcje |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $31 496 480 | 578 873 | 0,35% | Akcje |
| Arbejdsmarkedets Tillaegspension | $30 855 911 | 567 100 | 0,34% | Akcje |
| Pictet Asset Management Holding SA | $30 153 926 | 555 438 | 0,33% | Akcje |
| California Public Employees Retirement System | $29 366 600 | 539 728 | 0,32% | Akcje |
| CAPITAL FUND MANAGEMENT S.A. | $28 686 856 | 527 235 | 0,31% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $28 655 734 | 526 663 | 0,31% | Akcje |
| JANUS HENDERSON GROUP PLC | $26 675 806 | 621 814 | 0,29% | Akcje |
| Woodline Partners LP | $26 411 049 | 485 408 | 0,29% | Akcje |
| Driehaus Capital Management LLC | $26 025 500 | 478 322 | 0,29% | Akcje |
| EULAV Asset Management | $25 901 500 | 476 043 | 0,28% | Akcje |
| Squarepoint Ops LLC | $25 774 398 | 473 707 | 0,28% | Akcje |
| Swiss National Bank | $25 648 874 | 471 400 | 0,28% | Akcje |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $25 156 355 | 462 348 | 0,28% | Akcje |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24 600 555 | 452 133 | 0,27% | Akcje |
| IEQ CAPITAL, LLC | $24 580 697 | 451 768 | 0,27% | Akcje |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $23 831 580 | 438 000 | 0,26% | Akcje |
| Baird Financial Group, Inc. | $23 565 461 | 433 109 | 0,26% | Akcje |
| FRANKLIN RESOURCES INC | $23 480 472 | 431 547 | 0,26% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23 347 331 | 429 100 | 0,26% | Opcja kupna |
| Assenagon Asset Management S.A. | $23 324 098 | 428 673 | 0,26% | Akcje |
| BANK OF NOVA SCOTIA | $22 837 676 | 419 730 | 0,25% | Akcje |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $22 615 516 | 415 650 | 0,25% | Akcje |
| South Street Advisors LLC | $22 275 019 | 409 392 | 0,24% | Akcje |
| Bridgewater Associates, LP | $21 810 738 | 400 859 | 0,24% | Akcje |
| VICTORY CAPITAL MANAGEMENT INC | $21 480 143 | 394 783 | 0,24% | Akcje |
| ROYAL BANK OF CANADA | $20 031 000 | 368 153 | 0,22% | Akcje |
| SEI INVESTMENTS CO | $19 897 640 | 365 698 | 0,22% | Akcje |
| LAZARD ASSET MANAGEMENT LLC | $18 664 208 | 343 029 | 0,20% | Akcje |
| Nuveen, LLC | $18 299 226 | 336 321 | 0,20% | Akcje |
| Nuveen Asset Management, LLC | $18 252 629 | 548 127 | 0,20% | Akcje |
| NFJ INVESTMENT GROUP, LLC | $17 880 160 | 328 619 | 0,20% | Akcje |
| SAWGRASS ASSET MANAGEMENT LLC | $17 808 447 | 327 301 | 0,20% | Akcje |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $17 565 616 | 322 838 | 0,19% | Akcje |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $17 472 485 | 407 379 | 0,19% | Akcje |
| ING GROEP NV | $16 943 274 | 311 400 | 0,19% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $16 529 758 | 303 800 | 0,18% | Opcja sprzedaży |
| Brandywine Global Investment Management, LLC | $16 490 117 | 376 229 | 0,18% | Akcje |
| CAPTRUST FINANCIAL ADVISORS | $16 488 532 | 303 042 | 0,18% | Akcje |
| INTECH INVESTMENT MANAGEMENT LLC | $16 262 224 | 298 883 | 0,18% | Akcje |
| HighTower Advisors, LLC | $15 842 121 | 291 162 | 0,17% | Akcje |
| SEIZERT CAPITAL PARTNERS, LLC | $15 411 796 | 283 253 | 0,17% | Akcje |
| Trexquant Investment LP | $14 974 122 | 275 209 | 0,16% | Akcje |
| Clark Capital Management Group, Inc. | $14 792 882 | 271 878 | 0,16% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $14 763 381 | 344 215 | 0,16% | Akcje |
| VAN ECK ASSOCIATES CORP | $14 270 709 | 262 281 | 0,16% | Akcje |
| GLOBEFLEX CAPITAL L P | $13 874 169 | 254 993 | 0,15% | Akcje |
| Sofinnova Investments, Inc. | $13 831 022 | 254 200 | 0,15% | Opcja sprzedaży |
| JANE STREET GROUP, LLC | $13 815 570 | 253 916 | 0,15% | Akcje |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $13 724 052 | 252 234 | 0,15% | Akcje |
| Voleon Capital Management LP | $13 682 047 | 251 462 | 0,15% | Akcje |
| BLAIR WILLIAM & CO/IL | $13 233 352 | 243 215 | 0,15% | Akcje |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $13 027 000 | 239 418 | 0,14% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12 745 021 | 297 156 | 0,14% | Akcje |
| MERITAGE PORTFOLIO MANAGEMENT | $12 679 099 | 289 279 | 0,14% | Akcje |
| VANGUARD ASSET MANAGEMENT, Ltd | $12 516 694 | 230 044 | 0,14% | Akcje |
| Susquehanna Portfolio Strategies, LLC | $12 500 643 | 229 749 | 0,14% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $12 035 492 | 221 200 | 0,13% | Opcja kupna |
| Illinois Municipal Retirement Fund | $11 750 764 | 215 967 | 0,13% | Akcje |
| CWM, LLC | $11 300 486 | 263 476 | 0,12% | Akcje |
Insiderzy spółki 43 insiderów · 22 dyrektorzy generalni · 10 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Michael Morrissey | President and CEO | 18 maja 2026 G | 2 004 327 | 0 | 0 | $0 |
| Christopher J. Senner | EVP and CFO | 18 maja 2026 S | 952 317 | 0 | 3 | $-4 556 048 |
| Deborah Burke | SVP & Chief Financial Officer | 15 listopada 2014 M | 18 156 | 0 | 0 | $0 |
| Frank Karbe | EVP and CFO | 15 lutego 2014 M | 93 990 | 0 | 0 | $0 |
| Kristine M Ball | Controller & Interim CFO | 10 grudnia 2003 A | 4 913 | 0 | 0 | $0 |
| Patrick J. Haley | EVP, Commercial | 20 maja 2026 S | 357 638 | 0 | 7 | $-7 597 268 |
| Brenda Hefti | SVP and General Counsel | 18 maja 2026 S | 106 762 | 0 | 2 | $-1 154 264 |
| Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | 16 maja 2025 M | 465 393 | 0 | 0 | $0 |
| Jeffrey Hessekiel | EVP & General Counsel | 15 maja 2025 S | 693 396 | 0 | 0 | $0 |
| Vicki L Goodman | EVP, Prod Dev & Med Aff &CMO | 3 kwietnia 2023 A | 307 654 | 0 | 0 | $0 |
| Peter Lamb | EVP, Scientific Strategy & CSO | 15 grudnia 2022 M | 410 958 | 0 | 0 | $0 |
| Gisela Schwab | Pres, Prod Dev & Med Aff & CMO | 26 lipca 2021 M | 689 078 | 0 | 0 | $0 |
| Pamela A Simonton | EVP and General Counsel | 15 listopada 2013 M | 17 139 | 0 | 0 | $0 |
| Lupe M Rivera | EVP, Operations | 15 sierpnia 2011 M | 19 219 | 0 | 0 | $0 |
| Frances K Heller | EVP, Business Development | 15 maja 2011 M | 17 125 | 0 | 0 | $0 |
| Ian D Malcolm | VP, STRATEGIC MARKETING | 8 grudnia 2006 A | — | 0 | 0 | $0 |
| Christoph Pereira | VP, Legal Affairs & Secretary | 8 grudnia 2006 A | — | 0 | 0 | $0 |
| Jeffrey Latts | Executive VP, Development | 8 grudnia 2006 A | — | 0 | 0 | $0 |
| Gregory Plowman | Sr VP, CSO | 13 grudnia 2004 A | — | 0 | 0 | $0 |
| Steven P James | Sr VP, Commercial Ops | 10 grudnia 2003 A | — | 0 | 0 | $0 |
| Jane M Green | VP, Corp Communications | 10 grudnia 2003 A | — | 0 | 0 | $0 |
| Geoffrey M Duyk | Pres R&D & CSO | 4 listopada 2003 S | 941 355 | 0 | 0 | $0 |
| Alan M Garber | Dyrektor | 21 marca 2024 M | 35 703 | 0 | 0 | $0 |
| Jacqueline Wright | Dyrektor | 1 czerwca 2023 A | 51 756 | 0 | 0 | $0 |
| Carl B Feldbaum | Dyrektor | 9 lutego 2023 M | 18 701 | 0 | 0 | $0 |
| Lance Willsey | Dyrektor | 26 maja 2022 A | 424 415 | 0 | 0 | $0 |
| Vincent T Marchesi | Dyrektor | 26 maja 2022 A | 93 989 | 0 | 0 | $0 |
| Charles Cohen | Dyrektor | 6 lipca 2021 M | 261 375 | 0 | 0 | $0 |
| George A Scangos | Dyrektor | 18 maja 2020 S | 714 717 | 0 | 0 | $0 |
| FORMELA JEAN FRANCOIS | Dyrektor | 7 września 2005 S | 584 519 | 0 | 0 | $0 |
| Mary C Beckerle | — | 10 sierpnia 2026 S | 16 079 | 0 | 4 | $-1 932 572 |
| Sue Gail Eckhardt | — | 1 czerwca 2026 S | 16 079 | 0 | 2 | $-660 828 |
| Jack L Wyszomierski | — | 1 czerwca 2026 S | 284 384 | 0 | 2 | $-4 580 661 |
| Tomas J. Heyman | — | 27 maja 2026 A | 50 649 | 0 | 0 | $0 |
| Bob Oliver | — | 27 maja 2026 A | 29 487 | 0 | 2 | $-1 325 340 |
| Julie Smith | — | 27 maja 2026 A | 28 957 | 0 | 3 | $-4 687 346 |
| Maria C Freire | — | 27 maja 2026 A | 109 186 | 0 | 1 | $-949 164 |
| Stelios Papadopoulos | — | 27 maja 2026 A | 1 197 595 | 0 | 1 | $-4 355 000 |
| George Poste | — | 27 maja 2026 A | 127 199 | 0 | 1 | $-2 742 600 |
| Dana Aftab | — | 26 maja 2026 S | 594 741 | 0 | 4 | $-7 701 255 |
| Frank Mccormick | — | 6 grudnia 2013 A | — | 0 | 0 | $0 |
| Scott J. Garland | — | 18 września 2013 A | — | 0 | 0 | $0 |
| Jason S Fisherman | — | 8 września 2005 S | 7 881 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 4 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Farallon Capital Management, L.L.C., Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Roberts, Jr., Thomas G., Saito Edric C., Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. | 14 sierpnia 2026 | 5,60% | Aneks | — | SEC |
| Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Institutional Partners II, L.P., Farallon Capital Institutional Partners III, L.P., Four Crossings Institutional Partners V, L.P., Farallon Capital Offshore Investors II, L.P., Farallon Capital (AM) Investors, L.P., Farallon Capital F5 Master I, L.P., Farallon Healthcare Partners Master, L.P., Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C., Farallon Healthcare Partners (GP), L.L.C., Dapice Joshua J., Dreyfuss, Philip D., Dunn Hannah E., Fried, Richard B, Gehani, Varun N., Giauque, Nicolas, Husen, Avner A., Kim, David T., Linn, Michael G., Luo Patrick (Cheng), Patel, Rajiv A., Roberts, Jr., Thomas G., Saito Edric C., Seybold, William, Short Daniel S., Spokes, Andrew J. M., Warren, John R., Wehrly, Mark C. ×8 zgłoszenia | 5 stycznia 2026 | 5,90% | Aneks | — | SEC |
| Caligan Partners LP, David Johnson ×3 zgłoszenia | 2 czerwca 2023 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 29 listopada 2001 | — | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 152 fundusze ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| IDNA · iShares Trust | 3,47% | 131 275 SH | 8 sierpnia 2026 | Dziennie |
| SAWG · ETF Series Solutions | 2,82% | 1 599 NS | 30 kwietnia 2026 | N-PORT |
| CANC · Tema ETF Trust | 2,78% | 96 885 NS | 31 maja 2026 | N-PORT |
| XMHQ · Invesco Exchange-Traded Fund Trust | 2,67% | 2 774 135 SH | 8 sierpnia 2026 | Dziennie |
| PBE · Invesco Exchange-Traded Fund Trust | 2,59% | 173 519 SH | 8 sierpnia 2026 | Dziennie |
| MCOW · Pacer Funds Trust | 2,38% | 528 NS | 30 kwietnia 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 2,24% | 441 186 NS | 30 kwietnia 2026 | N-PORT |
| LYLD · Cambria ETF Trust | 2,01% | 2 722 NS | 30 kwietnia 2026 | N-PORT |
| AZTD · Tidal Trust I | 1,92% | 18 950 NS | 30 kwietnia 2026 | N-PORT |
| GRPM · Invesco Exchange-Traded Fund Trust | 1,84% | 172 947 SH | 8 sierpnia 2026 | Dziennie |
| BBP · ETFis Series Trust I | 1,74% | 23 148 NS | 30 kwietnia 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 1,61% | 1 596 NS | 30 kwietnia 2026 | N-PORT |
| BUL · Pacer Funds Trust | 1,45% | 41 520 NS | 30 kwietnia 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1,39% | 306 870 NS | 30 kwietnia 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1,36% | 5 563 NS | 30 kwietnia 2026 | N-PORT |
| RFG · Invesco Exchange-Traded Fund Trust | 1,30% | 86 397 SH | 8 sierpnia 2026 | Dziennie |
| PTH · Invesco Exchange-Traded Fund Trust | 1,29% | 58 887 SH | 8 sierpnia 2026 | Dziennie |
| COWG · Pacer Funds Trust | 1,26% | 616 432 NS | 30 kwietnia 2026 | N-PORT |
| TAX · EA Series Trust | 1,13% | 5 692 NS | 29 maja 2026 | N-PORT |
| CALF · Pacer Funds Trust | 1,07% | 829 382 NS | 30 kwietnia 2026 | N-PORT |
| AFMC · First Trust Exchange-Traded Fund VI… | 1,03% | 32 938 NS | 31 maja 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 1,00% | 116 281 NS | 30 kwietnia 2026 | N-PORT |
| IBB · iShares Trust | 0,98% | 1 788 613 SH | 8 sierpnia 2026 | Dziennie |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,93% | 13 681 SH | 8 sierpnia 2026 | Dziennie |
| AGNG · Global X Funds | 0,92% | 14 988 NS | 31 maja 2026 | N-PORT |
| OASC · Unified Series Trust | 0,91% | 15 171 NS | 31 maja 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,90% | 25 550 NS | 30 kwietnia 2026 | N-PORT |
| FLOW · Global X Funds | 0,90% | 5 093 NS | 31 maja 2026 | N-PORT |
| VAMO · Cambria ETF Trust | 0,88% | 16 470 NS | 30 kwietnia 2026 | N-PORT |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,72% | 248 016 SH | 8 sierpnia 2026 | Dziennie |
| FLRG · FIDELITY COVINGTON TRUST | 0,72% | 45 672 NS | 30 kwietnia 2026 | N-PORT |
| IJK · iShares Trust | 0,70% | 1 469 020 SH | 8 sierpnia 2026 | Dziennie |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,69% | 7 149 NS | 31 maja 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,68% | 82 717 NS | 31 maja 2026 | N-PORT |
| BIB · ProShares Trust | 0,66% | 9 600 NS | 31 maja 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,64% | 4 091 NS | 31 maja 2026 | N-PORT |
| VUSE · ETF Series Solutions | 0,63% | 85 930 NS | 31 maja 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,60% | 2 080 NS | 30 kwietnia 2026 | N-PORT |
| PDP · Invesco Exchange-Traded Fund Trust | 0,59% | 165 207 SH | 8 sierpnia 2026 | Dziennie |
| QGRO · AMERICAN CENTURY ETF TRUST | 0,58% | 255 026 NS | 31 maja 2026 | N-PORT |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0,53% | 19 762 NS | 31 maja 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 0,51% | 502 NS | 30 kwietnia 2026 | N-PORT |
| VFQY · VANGUARD WELLINGTON FUND | 0,49% | 42 746 SH | 8 sierpnia 2026 | Dziennie |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,48% | 64 828 NS | 30 kwietnia 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,47% | 5 095 NS | 30 kwietnia 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,45% | 147 282 SH | 8 sierpnia 2026 | Dziennie |
| IQSM · New York Life Investments ETF Trust | 0,44% | 30 864 NS | 30 kwietnia 2026 | N-PORT |
| XJH · iShares Trust | 0,41% | 33 981 SH | 8 sierpnia 2026 | Dziennie |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,41% | 47 960 NS | 30 kwietnia 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,41% | 33 169 SH | 8 sierpnia 2026 | Dziennie |